Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

6.700 -0.220 (-3.18%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Phathom Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Where Phathom Pharmaceuticals Stands With Analysts ↗

February 10, 2023

Via Benzinga

Phathom Pharma Shares Fall After Formal FDA Request For Vonoprazan Data ↗

February 10, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 10, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 09, 2023

Via Benzinga

Phathom Pharmaceuticals Provides Regulatory Updates

February 09, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

BMO Capital Maintains Outperform Rating for Phathom Pharmaceuticals: Here's What You Need To Know ↗

January 04, 2023

Via Benzinga

TOP RANKED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT

February 09, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Credit Acceptance, and Phathom and Encourages Investors to Contact the Firm

February 03, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Why Shares of Phathom Pharmaceutical Jumped This Week ↗

January 28, 2023

Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy.

Via The Motley Fool

Seagate, Boot Barn, Tesla And Other Big Stocks Moving Higher On Thursday ↗

January 26, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm

January 18, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm

January 11, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket ↗

January 09, 2023

Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy the company for up to $1.8 billion.

Via Benzinga

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

January 08, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Dow Gains 150 Points After Fed Minutes ↗

January 04, 2023

U.S. stocks traded higher toward the end of trading, following the release of minutes from the FOMC meeting.

Via Benzinga

Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 04, 2023

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

January 04, 2023

Via Benzinga

Nasdaq Rises Over 100 Points; Crude Oil Drops Sharply ↗

January 04, 2023

U.S. stocks extended gains midway through trading, with the Dow Jones gaining around 250 points on Wednesday ahead of the release of minutes from the Fed's meeting.

Via Benzinga

US Stocks Open Higher Ahead Of Fed Minutes; Dow Rises 100 Points ↗

January 04, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Wednesday.

Via Benzinga

FDA Issues No Action Notice For Phathom Pharma's Investigational Candidate, Shares Plunge ↗

January 04, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 04, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

January 04, 2023

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!

Via InvestorPlace

Vera Therapeutics, Phathom Pharmaceuticals And Some Other Big Stocks Moving Lower In Today's Pre-Market Session ↗

January 04, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis

January 03, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗

December 27, 2022

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

Via Benzinga

Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session ↗

December 13, 2022

Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.

Via Benzinga

NASDAQ:PHAT Shareholder Alert: Investigation over Possible Securities Laws Violations by Phathom Pharmaceuticals, Inc. ↗

November 15, 2022

San Diego, CA -- (SBWIRE) -- 11/15/2022 -- Phathom Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 08, 2022

From Phathom Pharmaceuticals

Via GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences

November 03, 2022

From Phathom Pharmaceuticals

Via GlobeNewswire

Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement

November 01, 2022

From Phathom Pharmaceuticals

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.